Article

A Clinical Research of Ceritinib Treating Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer With Brain Metastasis

2021-10-26

Abstract excerpt

<h4>Objective: </h4> As a second-generation oral anaplastic lymphoma kinase (ALK) inhibitor, ceritinib was recommended as posterior line therapy in patients with crizotinib resistance or intolerance. While in the real world, the clinical efficacy and safety of ceritinib, 450mg/d, taken with a low-fat meal in crizotinib resistant patients, especially with brain metastases, are still to be further investigated. Meth...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4e4e386d-eeaa-5fc3-897a-98661c6bc8db
DOI: 10.21203/rs.3.rs-983285/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Clinical Research of Ceritinib Treating Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer With Brain MetastasisDOI 10.21203/rs.3.rs-983285/v1Read

Integration of ceritinib and bevacizumab as a promising treatment strategy for brain metastases from ALK mutation-position non-small cell lung cancer: a case reportSemantic proximity Read

Pembrolizumab plus bevacizumab achieves long-term progression free survival in patients with lung adenocarcinoma with brain metastases: a case report and literature reviewSemantic proximity Read

Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis.Semantic proximity Read

Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.Semantic proximity Read

[Treatment of Patients with ALK-positive Non-small Cell Lung Cancer and Brain Metastases].Semantic proximity Read

Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.Semantic proximity Read

Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II studySemantic proximity Read

Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC.Semantic proximity Read

Treatment Strategy of Lung Adenocarcinoma with Concomitant EGFR Mutation and ALK RearrangementSemantic proximity Read

Treatment of Alectinib in NSCLC with Brain Metastasis Patient Refractory to Radiotherapy after Resistance to Crizotinib: A Case Report and Literature ReviewSemantic proximity Read

Coexistence of a primary ALK-positive and MET14 exon skipping mutation double-fusion in one patient with NSCLC and response to crizotinib: A case report and literature review.Semantic proximity Read

Ceritinib for ALK-Rearranged Non–Small-Cell Lung CancerSemantic proximity Read